Clinical Edge Journal Scan

Is there a link between tea consumption and gastric cancer?


 

Key clinical point: Regular tea consumption shows a weak inverse association with risk for gastric cancer.

Major finding: Regular vs. nonregular tea drinkers had a significantly lower risk for gastric cancer (pooled odds ratio [OR] 0.91; 95% CI 0.85-0.97). Compared with nonregular tea drinkers, there was no difference in risk for gastric cancer in regular tea drinkers who consumed 1 to <2, 2 to <3, ≥3 cups ( Ptrend = .27). A lower risk was observed in studies from China, Japan, and Iran (OR 0.62; 95% CI 0.48-0.81) and from China and Japan (OR 0.67; 95% CI 0.49-0.91).

Study details: A pooled analysis of 34 studies including 13,121 patients with gastric cancer and 31,420 control individuals from the StoP Project (a consortium of epidemiological studies on gastric cancer) dataset.

Disclosures: This study was supported by Associazione Italiana per la Ricerca sul Cancro and Italian League for the Fight Against Cancer. The authors declared no competing interests.

Source: Martimianaki G et al. Tea consumption and gastric cancer: A pooled analysis from the Stomach cancer Pooling (StoP) Project consortium. Br J Cancer. 2022 (May 24). Doi: 10.1038/s41416-022-01856-w

Recommended Reading

Therapy trends in patients with mCRC after the second disease progression
MDedge Hematology and Oncology
Is iatrogenic tumor seeding a risk factor for metachronous CRC? Evidence suggests otherwise
MDedge Hematology and Oncology
Heavy drinking associated with increased risk for EOCRC irrespective of genetic risk
MDedge Hematology and Oncology
Refractory metastatic CRC: Raltitrexed plus S-1 betters regorafenib in prolonging survival
MDedge Hematology and Oncology
CRC with synchronous liver metastases: Outcomes of simultaneous laparoscopic vs. hybrid and open resection
MDedge Hematology and Oncology
Does high consumption of nuts and legumes protect against CRC?
MDedge Hematology and Oncology
Obesity and metabolic syndrome at younger ages may increase earlier-onset CRC risk
MDedge Hematology and Oncology
Multi-agent vs. single-agent adjuvant chemotherapy in elderly patients with stage III colon cancer
MDedge Hematology and Oncology
Advanced gastric cancer: Ramucirumab-irinotecan combo fails phase 2
MDedge Hematology and Oncology
Gastric cancer: Tumor mutational burden and outcomes with pembrolizumab
MDedge Hematology and Oncology